Becton Dickinson and (NYSE:BDX) had its price target cut by Citigroup from $289.00 to $279.00 in a research note published on Tuesday. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other research firms have also recently issued reports on BDX. Morgan Stanley boosted their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an equal weight rating in a report on Thursday, October 4th. Wells Fargo & Co boosted their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the company an outperform rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Royal Bank of Canada restated a hold rating and set a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. KeyCorp restated a buy rating and set a $264.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Piper Jaffray Companies dropped their price objective on Becton Dickinson and to $250.00 and set an overweight rating for the company in a report on Tuesday, November 6th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Becton Dickinson and currently has a consensus rating of Buy and a consensus target price of $253.79.

BDX opened at $234.50 on Tuesday. Becton Dickinson and has a 52-week low of $209.91 and a 52-week high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The firm has a market cap of $63.20 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 1.63 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The company had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the business earned $2.40 EPS. Becton Dickinson and’s revenue was up 39.0% compared to the same quarter last year. As a group, research analysts forecast that Becton Dickinson and will post 12.15 earnings per share for the current fiscal year.

In other Becton Dickinson and news, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the sale, the executive vice president now owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of BDX. Fundsmith Equity Fund L.P. bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $894,775,000. FMR LLC raised its position in shares of Becton Dickinson and by 13.7% in the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock worth $4,069,559,000 after acquiring an additional 2,049,874 shares in the last quarter. Charles Schwab Investment Advisory Inc. bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $291,167,000. Vontobel Asset Management Inc. raised its position in shares of Becton Dickinson and by 823.0% in the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock worth $250,205,000 after acquiring an additional 904,097 shares in the last quarter. Finally, Cornerstone Wealth Management LLC raised its position in shares of Becton Dickinson and by 233.6% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock worth $3,286,000 after acquiring an additional 453,623 shares in the last quarter. Institutional investors and hedge funds own 92.70% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.